This brief examines the economic and ethical challenges of orphan drug pricing in the United States. While the Orphan Drug Act of 1983 spurred innovation for rare diseases, it also created affordability issues and opportunities for market abuse. The paper explores policy options to balance innovation incentives with equitable access to life-saving treatments.

Published by   

   on   

January 7, 2026